WO2014190555A1 - 一种抗甲型流感病毒感染并止咳的中药组合物及其制备方法 - Google Patents

一种抗甲型流感病毒感染并止咳的中药组合物及其制备方法 Download PDF

Info

Publication number
WO2014190555A1
WO2014190555A1 PCT/CN2013/076598 CN2013076598W WO2014190555A1 WO 2014190555 A1 WO2014190555 A1 WO 2014190555A1 CN 2013076598 W CN2013076598 W CN 2013076598W WO 2014190555 A1 WO2014190555 A1 WO 2014190555A1
Authority
WO
WIPO (PCT)
Prior art keywords
influenza
grams
cough
virus infection
chinese medicine
Prior art date
Application number
PCT/CN2013/076598
Other languages
English (en)
French (fr)
Inventor
曲敬来
高雪
陈生
齐继贵
Original Assignee
Qu Jinglai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qu Jinglai filed Critical Qu Jinglai
Priority to PCT/CN2013/076598 priority Critical patent/WO2014190555A1/zh
Publication of WO2014190555A1 publication Critical patent/WO2014190555A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/71Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A61K36/718Coptis (goldthread)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06Fungi, e.g. yeasts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/19Acanthaceae (Acanthus family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/19Acanthaceae (Acanthus family)
    • A61K36/195Strobilanthes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/23Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/233Bupleurum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/31Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
    • A61K36/315Isatis, e.g. Dyer's woad
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484Glycyrrhiza (licorice)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534Mentha (mint)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/538Schizonepeta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/539Scutellaria (skullcap)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/63Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
    • A61K36/634Forsythia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/70Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/704Polygonum, e.g. knotweed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/71Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/75Rutaceae (Rue family)
    • A61K36/752Citrus, e.g. lime, orange or lemon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/78Saururaceae (Lizard's-tail family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/80Scrophulariaceae (Figwort family)
    • A61K36/808Scrophularia (figwort)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/85Verbenaceae (Verbena family)
    • A61K36/855Clerodendrum, e.g. glorybower
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/14Antitussive agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses

Definitions

  • the invention belongs to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for preventing influenza A virus infection and relieving cough and a preparation method thereof.
  • influenza A virus is a novel influenza A H1N1, influenza A H3N2 virus. Background technique
  • influenza virus is a member of the Orthomyxovirdae family, which is the causative agent of influenza and is a cyclical pandemic that poses a serious threat to human health.
  • the influenza virus is divided into three types: A, B, and C.
  • the pathogenic strains are mainly type A and type B, and type C is basically not pathogenic.
  • influenza A virus is the main pathogen of several worldwide influenza epidemics, and most of the world's current epidemic is A.
  • the type A virus can be divided into various subtypes, such as H1N1, H1N2, and brain 2.
  • Humans are susceptible to HI and H3 subtypes, and common influenza virus subtypes are H1N1, H1N2, H3N2, and the like.
  • the new type A H1N1 influenza virus has attracted more and more attention in the clinic, and it has often caused epidemics in the population. Since the discovery of the flu virus, there have been five world pandemic records in the 20th century, which occurred in 1900, 1918, 1957, 1968, and 1977, with the most serious epidemic in 1918, with more than 20 million deaths.
  • influenza A virus In China, there were 12 epidemics of moderate or intermediate influenza from 1953 to 1976. Each epidemic was caused by influenza A virus.
  • the outbreak of avian influenza in 2003 was also a respiratory tract caused by influenza A virus subtype. infectious disease.
  • the symptoms of human influenza A virus are similar to those of ordinary human influenza, including fever, cough, sore throat, body aches, headache, chills and fatigue. Some may also have diarrhea and vomiting. In severe cases, pneumonia and breathing may occur. Depletion, even death.
  • the flu outbreaks around 2009 have spread to more than 100 countries in just a few months, affecting about 90,000 people and killing hundreds of people. There are 1040 confirmed cases in 24 provinces in mainland China.
  • the method of prevention and treatment of influenza by Western medicine at home and abroad is to use the vaccine to prevent the occurrence of influenza according to the theory of antigen-antibody, but the vaccine has not been controlled in several preventions of influenza, because the antigen of the influenza is constantly changing, and the vaccine is It is often difficult to exceed the speed of virus mutation, and the vaccine used during the last influenza episode will lose its preventive effect on the next influenza outbreak, and the preventive effect of the vaccine is only 70% to 90%, so it is difficult to achieve comprehensive and effective prevention. effect.
  • the drugs used for anti-influenza A virus 1.
  • Amantadine drugs It is a commonly used anti-influenza drug in the clinic, but there are neurotoxicity, long-term drug-prone drug-resistant strains, influenza B virus and this time. Shortcomings such as the ineffective influenza A H1N1 flu virus; 2.
  • Neuraminidase inhibitors and antisense oligonucleotides Represents drugs such as the inhalant zanamivir and Gi lead's oral oseltamivir. Among them, oseltamivir (Duffy) is considered to be one of the most effective drugs for the treatment of influenza A (H1N1) virus, and "Duffy" directly targets the distribution.
  • the neuraminidase on the surface of the influenza virus inhibits the activity of neuraminidase, prevents the release of viral particles, and severes the diffusion chain of the virus, thereby achieving the purpose of suppressing influenza virus and treating influenza.
  • Duffy since the listing of oseltamivir, it has received reports of multiple flu patients using this drug to treat self-harm and paralysis; 2 FDA in 2004 In January, the application of oseltamivir in young children may cause excessive drug concentration in the brain, posing a potential safety problem; 3 taking oseltamivir for vomiting, nausea (without vomiting), insomnia, headache and abdominal pain, diarrhea, Difficulty, dizziness, fatigue, nasal congestion, sore throat and cough are obvious; 4 expensive; In summary, the prevention and control of influenza virus at home and abroad is still very serious, and the research on anti-influenza drugs and treatment methods has important practical significance.
  • the motherland medicine believes that the fire of exogenous feelings is caused by the direct feeling of warm evil, and the fire evil is more than warm, so there is a saying that "the temperature is the heat, the fire is the extreme”. Wind, cold, heat, dampness, dryness can be turned into fire, called “five gas fire", such as the four seasons of evil spring cold, autumn injury dry, can be fire. According to the inventor's long-term clinical exploration and summary, the flu is caused by the evil spirits of the fire. The disease spreads rapidly and is the cause of many diseases.
  • the disease is caused by the evil of heat
  • the pathogenesis is the evil of exogenous heat, invading the lungs, and then quickly entering the gas, volatility, causing yang stagnation, lung and stagnation, clinical manifestations of high fever, aversion to cold, cough and Muscle soreness and other symptoms of qi and qi.
  • the present inventors have been treated for anti-influenza A virus infection for 20 years in clinical treatment and experimental research, and believe that the treatment of influenza A virus infection requires both heat-clearing and detoxification, prevention of external evil heat, and chilling solutions. Leading evil out.
  • Traditional Chinese medicine not only has the advantages of low drug resistance, side effects and less adverse reactions, but also has a comprehensive effect of inhibiting viral replication, regulating immune function, improving blood circulation, antipyretic and analgesic, antibacterial and anti-inflammatory, and is unique in preventing and treating viral infections. Advantages and broad development prospects. Studies have shown that most of the traditional Chinese medicines for clearing away heat and detoxification have direct antiviral effects, such as forsythia, honeysuckle, and wine.
  • the composition is mainly composed of schisandra chinensis, viniferine, scrophulariaceae, orange red, platycodon, northern sapling, puffball, forsythia, burdock, licorice, and has the functions of clearing away heat and detoxifying, relieving cough and relieving cough, causing stagnation and diarrhea.
  • Fire and evil, lifting and co-investing, on the contrary, is conducive to the fire and evil, and does not hurt the righteousness, clinically used for anti-influenza A virus infection.
  • the medicament of the present invention can be combined with the raw materials medicinal wine jaundice and radix isatidis.
  • the medicament of the present invention can also be combined with the raw materials of cohosh and mint.
  • the medicament of the present invention can also be combined with the raw materials medicinal herbs, sage, and houttuynia.
  • the main technical problem solved by the present invention is to overcome the deficiencies of the prior art, and to provide a traditional Chinese medicine composition capable of effectively resisting influenza A virus infection and relieving cough and having no toxic side effects, and a preparation method thereof, which meets the needs of society.
  • a traditional Chinese medicine composition for infecting and relieving cough of influenza A virus comprising the following parts by weight of raw materials (the parts by weight may be in grams, or other units of measurement) ): 1-30 grams of schisandra, 1-30 grams of scutellaria, 1-30 grams of Scrophularia, 1-30 grams of orange, 1_30 grams of Campanulaceae, 1-30 grams of Bupleurum, 1-30 grams of puffball, even 1-30 grams of cockroach, 1-30 grams of burdock, 1 _ 15 grams of licorice.
  • the preferred dosages are: 5-25 g of schisandra chinensis, 1-10 g of viniferine, 1-10 g of scrophularia, 1-10 g of orange, 1-10 g of platycodon, 1-10 g of Bupleurum, p. 10 grams, 1-10 grams of forsythia, 1-15 grams of burdock, 1-10 grams of licorice.
  • the preparation method of the medicament of the present invention is as follows:
  • the prepared thick paste is mixed with granules commonly used auxiliary materials, granulated, dried and packaged into bags, thereby preparing granules which are resistant to influenza A virus infection and coughing; or mixing thick paste with common auxiliary materials for oral liquid, boiling Dilute with water, let stand, filter, mix and pack into bottles, then prepare oral liquid for anti-influenza A virus infection and cough; or add thick cream to sucrose, flavor, preservative, boil, dilute with water To 1000ml, to stand, filter, mix, and dispense, to obtain a syrup that is resistant to influenza A virus infection and cough, wherein the weight of the sucrose is >450g, and the flavoring agent is stevioside, sodium saccharin, Ansai Honey, glycyrrhizin, cyclohexane sulfamic acid, asparagine, alcohol sugar, aspartame, menthol, various flavors and various fruit flavors, in an amount of 0.
  • the dosage of sorbic acid and its potassium and sodium salt is ⁇ 0.3%, and the amount of methylparaben is ⁇ 0.05%.
  • the packaging material used for the dispensing is a glass bottle or a plastic bottle; or a thick paste to be prepared. It can be prepared into anti-A type by mixing with tablet common accessories and compressing it. Influenza virus infection and cough-relieving tablets; or adding thick cream to capsules commonly used excipients, drying, pulverizing and encapsulating, to prepare capsules that are resistant to influenza A virus infection and cough.
  • the prepared thick paste is mixed with granules commonly used auxiliary materials, granulated, dried and packaged into bags to prepare granules which are resistant to influenza A virus infection and cough; or thick paste mixed with common oral materials, boiled Dilute with water, let stand, filter, mix and pack into bottles, then prepare oral liquid for anti-influenza A virus infection and cough; or add thick cream to sucrose, flavor, preservative, boil, dilute with water To 1000ml, to stand, filter, mix, and dispense, to obtain a syrup that is resistant to influenza A virus infection and cough, wherein the weight of the sucrose is >450g, and the flavoring agent is stevioside, sodium saccharin, Ansai Honey, glycyrrhizin, cyclohexane sulfamic acid, Asparagine, alcohol sugar, aspartame, menthol, various flavors and various fruit flavors, the dosage is 0.
  • the preservative is sorbic acid and its potassium sodium salt is ⁇ 0. 3%, the amount of methylparaben is ⁇ 0.05%, the packaging material used for the sub-package is glass bottle, plastic bottle; or the prepared thick paste is mixed with the common auxiliary materials of the tablet, and can be prepared by tableting.
  • a tablet that is infected with anti-influenza A virus and coughs; or a thick paste is added to a capsule auxiliary ingredient, dried, pulverized and filled into capsules to prepare a capsule that is resistant to influenza A virus infection and coughs.
  • the preparation method is as follows:
  • the prepared thick paste is mixed with granules commonly used auxiliary materials, granulated, dried and packaged into bags to prepare granules which are resistant to influenza A virus infection and cough; or thick paste mixed with common oral materials, boiled Dilute with water, let stand, filter, mix and pack into bottles, then prepare oral liquid for anti-influenza A virus infection and cough; or add thick cream to sucrose, flavor, preservative, boil, dilute with water To 1000ml, to stand, filter, mix, and dispense, to obtain a syrup that is resistant to influenza A virus infection and cough, wherein the weight of the sucrose is > 450g, and the flavoring agent is stevioside, sodium saccharin, Ansai Honey, glycyrrhizin, cyclohexane sulfamic acid, asparagine, alcohol sugar, aspartame, menthol, various flavors and various fruit flavors, in an amount of 0.
  • the dosage of sorbic acid and its potassium and sodium salt is ⁇ 0.3%, and the amount of methylparaben is ⁇ 0.05%.
  • the packaging materials used for the dispensing are glass bottles and plastic bottles; or the thick paste to be prepared. It can be prepared by mixing with tablet common auxiliary materials and tableting. Influenza virus infection and cough tablets; thick paste or excipients commonly added to capsules, dried, pulverized into capsules, can be prepared as an anti-influenza A virus infection and cough capsule.
  • Houttuynia cordata If it is combined with the raw material medicinal herbs, Houttuynia cordata, and its preparation method is as follows:
  • the prepared thick paste is mixed with granules commonly used auxiliary materials, granulated, dried and packaged into bags to prepare granules which are resistant to influenza A virus infection and cough; or thick paste mixed with common oral materials, boiled Dilute with water, let stand, filter, mix and pack into bottles, then prepare oral liquid for anti-influenza A virus infection and cough; or add thick cream to sucrose, flavor, preservative, boil, dilute with water To 1000ml, to stand, filter, mix, and dispense, to obtain a syrup that is resistant to influenza A virus infection and cough, wherein the weight of the sucrose is > 450g, and the flavoring agent is stevioside, sodium saccharin, Ansai Honey, glycyrrhizin, cyclohexane sulfamic acid, asparagine, alcohol sugar, aspartame, menthol, various flavors and various fruit flavors, in an amount of 0.
  • the dosage of sorbic acid and its potassium and sodium salt is ⁇ 0.3%, and the amount of methylparaben is ⁇ 0.05%.
  • the packaging material used for the dispensing is a glass bottle or a plastic bottle; or a thick paste to be prepared. It can be prepared into anti-A type by mixing with tablet common accessories and compressing it. Influenza virus infection and cough tablet; gel or a thick paste was added Capsules are commonly used as excipients. They are dried and pulverized into capsules to prepare capsules that are resistant to influenza A virus infection and cough.
  • the traditional Chinese medicine composition of the present invention is added to various conventional excipients required for preparing different dosage forms, and is prepared into any common dosage form by using a conventional traditional Chinese medicine preparation method, such as granules, oral liquid, syrup, tablets, capsules, orally disintegrating tablets, Effervescent tablets, dropping pills, gargle, mouthwash.
  • a conventional traditional Chinese medicine preparation method such as granules, oral liquid, syrup, tablets, capsules, orally disintegrating tablets, Effervescent tablets, dropping pills, gargle, mouthwash.
  • the medicine of the invention selects the combination of the schisandra chinensis, the wine scutellaria, the scrophulariaceae, the orange red, the platycodon, the northern sapling, the puffball, the forsythia, the burdock, the licorice, and the combination of these drugs enables synergistic effects of the effects of the drugs, thereby being effective Influenza A virus infection and cough.
  • the schizonepeta sinensis and the micro-temperature are the main medicines in the prescription, which are used to treat the lungs and liver, have the effect of dispelling the wind and diarrhea, and are commonly used drugs for treating colds.
  • the main feature of this side is to reuse the slightly warmed schisandra chinensis in most of the heat-clearing and purging fire medicines, and as the main medicine in the prescription, this is because: 1.
  • the schisandra chinensis is slightly warm, but the temperature is not dry, and the square is used. It can prevent most of the heat-clearing and purging fire medicines from being too cold, avoiding the disadvantages of cold and cooling evil, and does not affect the main effects of prescription heat-clearing and purging fire; 2.
  • the schisandra chinensis has the effect of dissolving the wind and dispersing the wind, and synergizing with the northern Bupleurum
  • the larger doses in the range are more effective than the low-dose antiviral, and the synergistic effect of the prescriptions is better; its importance and ingenuity are self-evident.
  • Traditional doctors focus on clearing heat and purging fire. The medicines are all cold and cool, such as whitening.
  • the silkworm is clearing away heat and swallowing, but it has been clinically found that it is easy to diarrhea during the medication, and there are many problems such as coughing and refractory after heat retreat.
  • the root cause is that the prescription is too cold, and the clinical phenomenon is also found to be allergic to the animal silkworm. .
  • Another important feature of this side is the reuse of wine berberine, vinorenic acid and bitter cold, which can clear heat and dampness, purging fire and detoxification, and is the main component of Fangzhongqingjie.
  • wine and yoghurt can be connected to the stomach, which can be used for diarrhea and stomach fire.
  • Evil pass Yang Ming can be connected to the stomach, which can be used for diarrhea and stomach fire.
  • the traditional Chinese medicine composition of the invention can also be combined with wine scutellaria and radix scutellaria; this is because scutellaria sinensis is a famous traditional Chinese medicine for clearing heat and purging fire, phlegm and blood stasis, cold, heat and dampness, purging fire and detoxification, Shanqing Pulmonary fire and hot on the coke; Ban GmbH taste bitter cold, heart, stomach, function clearing heat and detoxification, cooling blood, pharynx, for fever, fever, headache, sore throat and many other hot poison blazing.
  • the traditional Chinese medicine composition of the present invention can also be combined with cohosh and mint; this is because the cohosh has the functions of clearing away heat and detoxifying, relieving the cold, and treating the wind and heat, and the headache of Yangming. It can treat the symptoms of exogenous wind-heat and wetness, and effectively improve the clinical curative effect; Mint Xin, cool, airy, into the lungs, liver, with evacuation of wind and heat, clearing the heat, clearing the wind, reducing swelling, relieving pain, commonly used In the hot cold, wind and heat headache, red eyes, sore throat and so on.
  • the traditional Chinese medicine composition of the invention can also be combined with the succulent grass and the houttuynia; this is because the succulent, bitter, slightly cold, the effect of clearing away heat and detoxifying, eliminating phlegm and draining pus, is applied to Heat poisoning bloated; Houttuynia sinensis, slightly cold, to the lungs, there is heat and detoxification, drainage effect, for lung heat cough and other cards.
  • the traditional Chinese medicine composition of the invention is a combination of the experience and practice in the clinical practice of the Chinese medicine epidemic for many years, and the scientific experimental basis, the components can not only exert their respective pharmacological effects, but also play a synergistic role to enhance the pharmacological action.
  • the formula is reasonable and the medicinal taste is refined.
  • the prescription is used for treating or preventing the infection of influenza A virus. As long as there is fever, cough, jaundice, sore throat, headache and body pain, it can be applied, the curative effect is exact, and no The toxic side effects are effective as a general purpose for both treatment and prevention during the epidemic period, and the dosage form and preparation process are suitable for industrial mass production.
  • the traditional Chinese medicine composition for infecting and relieving cough of the influenza A virus of the present invention comprises the following raw materials of the weight parts: 5-25 g of schisandra chinensis, 1-10 g of scutellaria, 1-10 g of Scrophularia sinensis, 1-10 of orange red Ke, Campanulaceae 1_10 grams, Bupleurum 1_10 grams, Mabul 1-10 grams, Forsythia 1-10 grams, 1-15 grams of burdock, 1-3 grams of licorice.
  • Embodiment 1 is a diagrammatic representation of Embodiment 1 :
  • ⁇ _ cyclodextrin heat to dissolve, stir, filter, spray dry hot air inlet air temperature 180 ° C, air temperature 80 ° C, spray dry powder to add flavoring, mix, the material is dried at 40 ° C
  • the granules are prepared by granulating, granulating and sub-packing into capsules, thereby obtaining granules of the present invention which are resistant to influenza A virus infection and cough.
  • Embodiment 2 Weigh 20 grams of the raw material schisandra, 10 grams of scutellaria, 5 grams of Scrophulariaceae, 5 grams of orange, 5 grams of Campanulaceae, 5 grams of Bupleurum, 5 grams of Mabul, 5 grams of Forsythia, 5 grams of burdock, licorice 5 g of the above ten flavors of a total of 70 g were then prepared into granules according to the method described in the first embodiment.
  • Embodiment 3 is a diagrammatic representation of Embodiment 3
  • Embodiment 4 is a diagrammatic representation of Embodiment 4:
  • Embodiment 5 is a diagrammatic representation of Embodiment 5:
  • Embodiment 6 is a diagrammatic representation of Embodiment 6
  • Embodiment 7 is a diagrammatic representation of Embodiment 7:
  • Embodiment 8 is a diagrammatic representation of Embodiment 8
  • Embodiment 9 is a diagrammatic representation of Embodiment 9:
  • MDCK dog kidney cells
  • Virus strain Influenza virus type A A / Guangdong defense / 243/72 (H3N2).
  • Sample treatment The thick paste prepared in Examples 1, 2, 3, 4, 5, 6, 7, 8, and 9 was dissolved in water and made into a solution of 1000 mg/ml for bottling; after centrifugation at 3000 rpm for 20 minutes. Take the supernatant and adjust the pH with 50% sodium citrate. 7. 2 ⁇ 7. 6, pour into a sterile test tube, autoclave at 121 °C for 15-20 minutes, remove and store at 4 °C in the refrigerator. Standby; the solution sample was diluted with a 1:10 dilution of the culture medium and diluted twice to a total of 8 dilutions.
  • MDCK cells were cultured in 96-well culture plates. After 24 hours, they were infected with influenza A (A)/Guangdong/243/72 (H3N2) (infection volume was 100 TCID50), adsorbed for 2 hours, and the virus solution was discarded. Add the sample according to the above dilution, set the cell control well and virus control well, observe the degree of cytopathic effect (CPE) for 24 hours, calculate the half effective concentration (IC 5 ) of the sample by Reed-Muench method, and calculate the drug selection index. (SI).
  • Embodiment Example 1 Group 1. 42 mg/mL 1. 61
  • Embodiment Example 2 Group 1. 23 mg/mL 2. 31
  • Embodiment Example 3 Group 1. 16 mg/mL 2. 88
  • Embodiment Example 4 Group 0. 43 mg/mL 5. 09
  • Embodiment Example 5 Group 0. 58 mg/mL 4. 21
  • Embodiment Example 6 Group 0. 03 mg/ml 6. 02
  • Embodiment Example 7 Group 0. 89 mg/mL 3. 60
  • Test Example 2 Experiment on the anti-influenza A virus subtype of Chinese traditional medicine
  • the group of schisandra chinensis 1 is a thick paste obtained by weighing the raw material medicine schisandra chinensis 12g according to the method of the first embodiment, and the schisandra chinensis 2 group is called the raw material medicine schisandra chinensis 20g according to the method of the first embodiment.
  • the obtained thick paste, the three groups of the schisandra chinensis were a thick paste obtained by weighing the raw material medicine Stevia sinensis 30g according to the method of the first embodiment; the windproof group was a thick cream prepared by the method of the first embodiment.
  • the control group was Tamiflu.
  • mice After inhaling the aerosol of irritating chemicals, the mice stimulate the respiratory sensilla and reflexively cause coughing.
  • mice 2 Animal Kunming mice 50, body weight (25 ⁇ 2) g, male and female, provided by the Animal Experimental Center of Shenzhen Hospital affiliated to Guangzhou University of Traditional Chinese Medicine, the mice in each group were normal before the experiment, no cough or other normal phenomenon.
  • the method is made into granules; the mass concentration of crude drug is 100g / lOOmL, and the crude drug is provided by the Chinese Pharmacy of Shenzhen Hospital affiliated to Guangzhou University of Traditional Chinese Medicine, all of which are in compliance with the relevant provisions of the Pharmacopoeia of the People's Republic of China.
  • Disodium loratadine dispersible tablet (trade name: Lei Ning, approval number: Guoji Zhunzi H20030208, 2010-12-08, production unit: Beijing Shuanglu Pharmaceutical Co., Ltd.).
  • Western medicine control group was given loratadine dispersible tablets 2mL / 20 g: blank group was orally administered with equal dose of distilled water. Once a day, the time is 4d.
  • mice were fasted for 12 hours, and after lh administration, they were placed in a 20cmX 20cmX 15cm closed plexiglass test chamber, and 50mL of concentrated ammonia water was placed in the atomizer, and passed to the experiment box. Atomized ammonia water for 30s. Immediately after the end, the mice were taken out and observed.
  • the number of coughs in the Kanggan stagnation granule group, the schizonepeta group and the western medicine control group was significantly lower than that of the blank control group and the Kanggan stagnation granules. It was effective for coughing in mice.
  • the effect of Kanggan Zhike Granules was particularly obvious, followed by the schisandra chinensis group, and the anti-sucking cough granules were basically ineffective in the schizonepeta group.
  • the experiment showed that the schizonepeta has a very good antitussive effect.
  • Test Example 4 Clinical efficacy test of traditional Chinese medicine composition against influenza A virus infection and relieving cough
  • This group of patients were diagnosed with new type A H1N1 influenza in 2009, aged 11 to 69 years, 90 patients who met the following diagnostic criteria, were randomly divided into treatment group (embodiment group 9) 30 cases, treatment 2 There were 30 cases in the group (Example group 6) and 30 cases in the control group (Tuffy). There were no significant differences in gender, age, duration of disease, and disease distribution between the groups (P>0.05).
  • Severe serious primary diseases such as viral hepatitis, hemophilia, diabetes, and mental illness, such as severe heart, brain, lung, liver, kidney and blood system;
  • a group of granules of traditional Chinese medicine composition administered in the group of Example 9 was administered orally twice a day. Each dose was equivalent to the amount of each raw medicine, see Example 9 group; treatment group 2 was administered (Example 6) Group) of traditional Chinese medicine composition granules, orally, twice daily, each dose is equivalent to the amount of each raw medicine, see Example 6 group; the control group is Tamiflu (oseltamivir phosphate capsule) 75mg / time, each 2 times a day, orally. Children are reduced. The course of treatment is 5 days.
  • the body temperature was normal within 24 hours, and the clinical symptoms such as cough and sore throat were alleviated.
  • the virus isolated from the nasopharyngeal swab was detected by RT-PCR, and the novel H1N1 virus RNA turned negative within 72 hours.
  • the clinical trials of the anti-influenza A virus infection were carried out by using the traditional Chinese medicine composition (the embodiment group 9 group) and the (the embodiment group 6 group) Chinese medicine composition and the control Tamifi group, and the results showed that: the three groups of patients were compared with fever, cough, expectoration, etc. Clinical improvement, 72-hour viral nucleic acid conversion rate, average fever time, etc.
  • the total effective rate of treatment for a group of patients was 59.33%, the viral nucleic acid conversion rate was 11.13%, and the average fever time was 41.23 hours.
  • the total effective rate of clinical improvement in the two groups was 71.58%, and the 72-hour viral nucleic acid conversion rate was 72 hours. 33.55%, the average fever time was 23.38 hours; the total effective rate of clinical improvement in the control group was 73.11%, the 72-hour viral nucleic acid conversion rate was 36.12%, and the average fever time was 27.06 hours.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

抗甲型流感病毒感染并止咳的中药组合物及其制备方法,该组合物保护荆芥穗1-30克、酒黄连1-30克、玄参1-30克、玄参1-30克、橘红1-30克、桔梗1-30克、北柴胡1-30克、马勃1-30克、连翘1-30克、牛蒡子1-30克、甘草1-15克。上述原料配以辅料和矫味剂,经过常规工序直接或间接制成药剂学上可接受的颗粒剂、口服液、糖浆、片剂、胶囊、口崩片、泡腾片、滴丸、含漱液、漱口水等多种剂型。

Description

一种抗甲型流感病毒感染并止咳的中药组合物及其制备方法 技术领域
本发明属于中药技术领域,特别是关于一种抗甲型流感病毒感染并止咳的中药组合 物及其制备方法。 其中, 所述的甲型流感病毒为甲型新型 H1N1、 甲型 H3N2流感病毒。 背景技术
流行性感冒病毒属正粘病毒科(Orthomyxovirdae )成员, 是流行性感冒的病原体, 并且呈周期性大流行, 严重威胁人类健康。 历史上世界各国均出现过流感大规模爆发, 死亡人数数以亿计。 流感病毒分为甲、 乙、 丙三种类型, 致病株主要是甲、 乙型, 丙型 基本不致病。其中甲型流感病毒是几次世界性流感流行的主要病原体, 而且目前世界上 流行的也多为甲型。根据病毒表面凸出的蛋白质一血凝素 (HA)和神经氨酸酶 (NA)的不同, 甲型病毒又可分为多种亚型, 如 H1N1、 H1N2、 腦 2等。 而人对其中的 HI和 H3亚型易感, 常见的流感病毒亚型为 H1N1、 H1N2、 H3N2等。 近几年来, 甲型新型 H1N1流感病毒在临床 中越发引起人们的重视, 在人群中常引发流行。 自发现流感病毒, 20世纪中有 5次世界 性大流行的记载, 分别发生于 1900、 1918、 1957、 1968和 1977年, 其中以 1918年的一次 流行最为严重, 死亡人数达 2000万以上。 我国从 1953年至 1976年已有 12次中等或中等以 上的流感流行, 每次流行均由甲型流感病毒所引起, 2003年爆发的禽流感也是一种由甲 型流感病毒亚型引起的呼吸道传染病。人感染甲型流感病毒后的症状与普通人流感相似, 包括发热、咳嗽、喉咙痛、身体疼痛、头痛、发冷和疲劳等,有些还会出现腹泻和呕吐, 重者会继发肺炎和呼吸衰竭,甚至死亡。 2009年前后爆发的流感短短几个月内即波及 100 余个国家, 感染约 9万人, 死亡数百人, 我国内地有 24个省份累计确诊病例 1040例。 并 且药敏提示此次爆发的甲型 H1N1流感病毒对金刚烷胺和金刚乙胺耐药。 国内外西医对流感的防治方法就是根据抗原抗体学说运用疫苗来预防流感的发生, 但疫苗在几次流感的预防观察中都未能控制流行,其原因是流感的抗原不断发生着变异, 疫苗的研发往往很难超越病毒变异的速度,且上一次流感发病期间所用的疫苗对下一次 流感爆发会失去预防作用,且疫苗的预防效果也只有 70%〜 90%, 因而难以起到全面有效 的预防作用。 而用于抗甲型流感病毒的药物: 1、 金刚烷胺类药物: 是目前临床上常用 的抗流感药物, 但存在神经毒性、 长期用药易产生耐药株、 对乙型流感病毒及此次爆发 的甲型 H1N1流感病毒无效等缺点; 2、 神经氨酸酶抑制剂和反义寡核苷酸: 代表药物如 吸入剂扎那米韦和 Gi lead公司推出的口服剂奥司他韦。 这其中奥司他韦(达菲)被认为 是目前治疗甲型 H1N1流感病毒相对最为有效的药物之一, "达菲"直接靶向作用在分布 于流感病毒表面的神经氨酸酶, 抑制神经氨酸酶的活性、 阻止病毒颗粒的释放, 切断病 毒的扩散链, 从而达到抑制流感病毒、 治疗流感的目的。 但在肯定其疗效的同时达菲应 用过程中存在诸多问题: ①自奥司他韦上市后, 已经陆续收到多份流感患者使用该药治 疗发生自我伤害和谵妄事件的报告; ② FDA于 2004年 1月声称奥司他韦应用于幼儿可能造 成脑内药物浓度过高,形成潜在的安全问题;③服用奥司他韦的呕吐、恶心(不伴呕吐)、 失眠、 头痛和腹痛、 腹泻、 头晕、 疲劳、 鼻塞、 咽痛和咳嗽等临床副作用明显; ④价格 昂贵; 综上所述, 国内外流感病毒的防治问题仍很严峻, 抗流感病毒药物及治疗方法的 研究具有重要的实际意义。 至今, 尚未找到针对甲型新型 H1N1、 甲型 H1N1、 甲型 H3N2流 感的疫苗和特效治疗药物。 因此, 寻找一种疗效明确的治疗及预防甲型新型 H1N1、 甲型 H1NK 甲型 H3N2流感药物成为医疗界关注的焦点和亟待解决的突出问题。
祖国医学认为, 外感之火由直接感受温热邪气所致, 火邪甚于温热, 所以有 "温 为热之渐, 火乃热之极"之说。 风、 寒、 暑、 湿、 燥入里皆可化火, 称为 "五气化火", 如四时感邪之春伤风、 秋伤燥, 均可化火。 据发明人长年临床探索发现并总结, 流感均 是由火热之邪气所致, 此病传播迅速, 是多种疾病的起因, 常入里化热。 病因为火热之 邪, 病机为外感火热之邪, 侵袭肺卫, 后迅速进入气分, 伏于气分, 致阳气郁热, 肺卫 郁闭, 临床上表现为高热、 恶寒、 咳嗽及肌肉酸痛等卫气同病的症状。 本发明人通过抗 甲型流感病毒感染二十年的临床治疗及实验研究, 认为治疗甲型流感病毒感染, 既要清 热解毒, 防止外邪化热造成种种变证, 又要辛凉解表, 引邪外出。
中药不仅具有耐药性低、 副作用和不良反应少等优点, 而且还有抑制病毒复制、 调 节免疫功能、 改善血液循环、 解热镇痛及抗菌消炎等综合功效, 其在防治病毒感染方面 具有独特的优势和广阔的发展前景。研究表明, 清热解毒类中药大多具有直接抗病毒的 作用, 如连翘、 金银花、 酒黄连等。
发明内容
本研究就是针对上述病因病机,采用有针对性而且具有独特抗甲型流感病毒感染并 止咳作用的中草药配制而成。 该组合物主要由荆芥穗、 酒黄连、 玄参、 橘红、 桔梗、 北 柴胡、 马勃、 连翘、 牛蒡子、 甘草组成, 具有清热解毒、 解表止咳之功, 因势利导, 疏 风泻火散邪, 升降共投, 相反相成, 既有利于火邪清解, 又达到不伤正气, 临床上可用 于抗甲型流感病毒感染。
为达到更好的疗效, 本发明药物可与原料药酒黄芩、 板蓝根相结合。
为达到更好的疗效, 本发明药物还可与原料药升麻、 薄荷相结合。 为达到更好的疗效, 本发明药物还可与原料药败酱草、 鱼腥草相结合。 本发明所解决的主要技术问题是克服现有技术的不足,提供一种能够有效抗甲型流 感病毒感染并止咳且无毒副作用的中药组合物及其制备方法, 满足社会的需求。
本发明解决其技术问题所采用的技术方案是:一种抗甲型流感病毒感染并止咳的中 药组合物,包括下列重量份数的原料药(重量份数可以以克为单位,或者其他计量单位): 荆芥穗 1-30克、 酒黄连 1-30克、 玄参 1-30克、 橘红 1-30克、 桔梗 1_30克、 北柴胡 1-30克、 马勃 1-30克、 连翘 1-30克、 牛蒡子 1-30克、 甘草 1_15克。
优选用量为: 荆芥穗 5-25克、 酒黄连 1-10克、 玄参 1-10克、 橘红 1-10克、 桔梗 1-10克、北柴胡 1-10克、马勃 1-10克、连翘 1-10克、牛蒡子 1-15克、甘草 1-10克。
本发明药物的制备方法如下:
取原料药荆芥穗、 酒黄连、 玄参、 橘红、 桔梗、 北柴胡、 马勃、 连翘、 牛蒡子、 甘 草加水煎煮合并滤液、 浓縮、 冷却, 加乙醇使含醇量 20-80% ( V/V) ,回收乙醇, 使上 清液浓縮成稠膏,备用。将制备的稠膏与颗粒剂常用辅料混合,制粒,干燥和分装成袋, 即可制备成抗甲型流感病毒感染并止咳的颗粒剂; 或将稠膏与口服液常用辅料混合, 煮 沸, 加水稀释, 静置, 过滤, 混匀分装成瓶, 即可制备成抗甲型流感病毒感染并止咳的 口服液; 或将稠膏加入蔗糖、 矫味剂、 防腐剂, 煮沸, 加水稀释至 1000ml , 静置, 滤 过, 混匀, 分装, 即得抗甲型流感病毒感染并止咳的糖浆, 其中所述蔗糖重量〉 450g, 所述矫味剂为甜菊苷、糖精钠、安塞蜜、甘草甜素、环已烷氨基磺酸、天冬酰胺、醇糖、 天冬甜精、 薄荷脑、 各种香精及各种果味料, 用量为 0.广 10%, 所述防腐剂为山梨酸及 其钾钠盐用量为<0. 3%、 羟苯甲酯类用量为 <0. 05 %, 所述分装使用的包材为玻璃瓶、 塑料瓶; 或将制备的稠膏与片剂常用辅料混合、压片, 即可制备成抗甲型流感病毒感染 并止咳的片剂; 或将稠膏加入胶囊剂常用辅料, 干燥、 粉碎装入胶囊, 即可制备成抗甲 型流感病毒感染并止咳的胶囊。
如果还与原料药酒黄芩、 板蓝根结合, 其制备方法为:
取原料药荆芥穗、 酒黄连、 玄参、 橘红、 桔梗、 北柴胡、 马勃、 连翘、 牛蒡子、 甘 草、 酒黄芩、 板蓝根加水煎煮合并滤液、 浓縮、 冷却, 加乙醇使含醇量 20-80% (V/V), 回收乙醇, 使上清液浓縮成稠膏, 备用。 将制备的稠膏与颗粒剂常用辅料混合, 制粒, 干燥和分装成袋, 即可制备成抗甲型流感病毒感染并止咳的颗粒剂; 或将稠膏与口服液 常用辅料混合, 煮沸, 加水稀释, 静置, 过滤, 混匀分装成瓶, 即可制备成抗甲型流感 病毒感染并止咳的口服液; 或将稠膏加入蔗糖、 矫味剂、 防腐剂, 煮沸, 加水稀释至 1000ml , 静置, 滤过, 混匀, 分装, 即得抗甲型流感病毒感染并止咳的糖浆, 其中所述 蔗糖重量〉 450g,所述矫味剂为甜菊苷、糖精钠、安塞蜜、甘草甜素、环已烷氨基磺酸、 天冬酰胺、 醇糖、 天冬甜精、 薄荷脑、 各种香精及各种果味料, 用量为 0.广 10%, 所述 防腐剂为山梨酸及其钾钠盐用量为 <0. 3%、羟苯甲酯类用量为 <0. 05 %, 所述分装使用 的包材为玻璃瓶、 塑料瓶; 或将制备的稠膏与片剂常用辅料混合、 压片, 即可制备成抗 甲型流感病毒感染并止咳的片剂;或将稠膏加入胶囊剂常用辅料,干燥、粉碎装入胶囊, 即可制备成抗甲型流感病毒感染并止咳的胶囊。
如果还与原料药升麻、 薄荷结合, 其制备方法为:
取原料药荆芥穗、 酒黄连、 玄参、 橘红、 桔梗、 北柴胡、 马勃、 连翘、 牛蒡子、 甘 草、 酒黄芩、 板蓝根、 升麻、 薄荷加水煎煮合并滤液、 浓縮、 冷却, 加乙醇使含醇量 20-80% (V/V),回收乙醇, 使上清液浓縮成稠膏, 备用。 将制备的稠膏与颗粒剂常用辅 料混合, 制粒, 干燥和分装成袋, 即可制备成抗甲型流感病毒感染并止咳的颗粒剂; 或 将稠膏与口服液常用辅料混合, 煮沸, 加水稀释, 静置, 过滤, 混匀分装成瓶, 即可制 备成抗甲型流感病毒感染并止咳的口服液;或将稠膏加入蔗糖、矫味剂、防腐剂,煮沸, 加水稀释至 1000ml , 静置, 滤过, 混匀, 分装, 即得抗甲型流感病毒感染并止咳的糖 浆, 其中所述蔗糖重量〉 450g, 所述矫味剂为甜菊苷、 糖精钠、 安塞蜜、 甘草甜素、 环 已烷氨基磺酸、 天冬酰胺、 醇糖、 天冬甜精、 薄荷脑、 各种香精及各种果味料, 用量为 0.广 10%,所述防腐剂为山梨酸及其钾钠盐用量为 <0. 3%、羟苯甲酯类用量为 <0. 05 % , 所述分装使用的包材为玻璃瓶、 塑料瓶; 或将制备的稠膏与片剂常用辅料混合、 压片, 即可制备成抗甲型流感病毒感染并止咳的片剂; 或将稠膏加入胶囊剂常用辅料, 干燥、 粉碎装入胶囊, 即可制备成抗甲型流感病毒感染并止咳的胶囊。
如果还与原料药败酱草、 鱼腥草结合, 其制备方法为:
取原料药荆芥穗、 酒黄连、 玄参、 橘红、 桔梗、 北柴胡、 马勃、 连翘、 牛蒡子、 甘 草、 酒黄芩、 板蓝根、 升麻、 薄荷、 败酱草、 鱼腥草加水煎煮合并滤液、 浓縮、 冷却, 加乙醇使含醇量 20-80% (V/V) ,回收乙醇, 使上清液浓縮成稠膏, 备用。 将制备的稠 膏与颗粒剂常用辅料混合, 制粒, 干燥和分装成袋, 即可制备成抗甲型流感病毒感染并 止咳的颗粒剂; 或将稠膏与口服液常用辅料混合, 煮沸, 加水稀释, 静置, 过滤, 混匀 分装成瓶, 即可制备成抗甲型流感病毒感染并止咳的口服液; 或将稠膏加入蔗糖、矫味 剂、 防腐剂, 煮沸, 加水稀释至 1000ml , 静置, 滤过, 混匀, 分装, 即得抗甲型流感 病毒感染并止咳的糖浆, 其中所述蔗糖重量〉 450g, 所述矫味剂为甜菊苷、 糖精钠、 安 塞蜜、 甘草甜素、 环已烷氨基磺酸、 天冬酰胺、 醇糖、 天冬甜精、 薄荷脑、 各种香精及 各种果味料, 用量为 0.广 10%, 所述防腐剂为山梨酸及其钾钠盐用量为 <0. 3%、 羟苯甲 酯类用量为 <0. 05 %, 所述分装使用的包材为玻璃瓶、 塑料瓶; 或将制备的稠膏与片剂 常用辅料混合、压片, 即可制备成抗甲型流感病毒感染并止咳的片剂; 或将稠膏加入胶 囊剂常用辅料, 干燥、 粉碎装入胶囊, 即可制备成抗甲型流感病毒感染并止咳的胶囊。 本发明中药组合物加入制备不同剂型时所需的各种常规辅料,运用常规的中药制剂 方法制备成任何一种常用剂型, 如颗粒剂、 口服液、 糖浆、 片剂、 胶囊、 口崩片、 泡腾 片、 滴丸、 含嗽液、 漱口水。
本发明药物选择荆芥穗、 酒黄连、 玄参、 橘红、 桔梗、 北柴胡、 马勃、 连翘、 牛蒡 子、甘草进行组合, 将这些药物组合使得各药物功效产生协同作用, 从而能够有效抗甲 型流感病毒感染并止咳。其中荆芥穗辛、微温为方中之主药,归肺、肝经,有解表散风、 透疹的功效, 是治疗感冒的常用药。 张寿颐云:荆芥, 治风热在表在上诸症, 能泄肺热 而达皮毛, 风热咳嗽宜之。 《滇南本草》 :荆芥穗, 解肺、 肝、 咽喉热痛 ......通肺气鼻窍 塞闭; 酒黄连苦, 寒, 无毒, 归心、 脾、 胃、 肝、 胆、 大肠经, 功可清热燥湿, 泻火解 毒, 主治湿热痞满, 呕吐吞酸, 泻痢, 黄疸, 高热神昏, 心火亢盛, 心烦不寐, 血热吐 衄, 目赤, 牙痛, 消渴, 痈肿疔疮; 玄参味甘、 苦、 咸, 性微寒, 归肺、 胃、 肾经, 功 擅清热凉血, 泻火解毒, 滋阴, 主治温邪入营, 内陷心包, 温毒发斑, 热病伤阴、 舌絳 烦渴、 津伤便秘、 骨蒸劳嗽、 目赤、 咽痛、 瘰疬、 白喉、 痈肿疮毒; 少量橘红辛、 苦, 性温, 归肺、 脾经, 功能散寒、 燥湿、 利气、 消痰, 用于治疗咳嗽, 喉痒痰多, 食积伤 酒, 呕恶痞闷; 少量桔梗味苦、 辛、 性微温, 入肺经, 能祛痰止咳, 并有宣肺、 排脓作 用,用于咳嗽痰多、咽喉肿痛、肺痈吐脓、胸满胁痛; 柴胡味辛苦,气微寒, 芳香疏泄, 能条达肝气, 疏肝解郁, 疏散少阳半表半里之邪, 为改善胸胁苦满、 口苦咽干等少阳证 之要药; 北柴胡长于解热泄下, 推陈致新, 发明人通过临床应用发现其疏导邪气, 解表 退热的作用优于南柴胡; 马勃辛、 平, 归肺经, 善于清肺、 利咽、 解毒、 止血, 用于肺 热咳嗽、 失音、 咽喉肿痛等证; 连翘苦、 微寒, 归肺、 心、 胆经, 功效清热解毒, 消痈 散结, 用于外感风热或温病初起、发热、头痛、 口渴等证; 牛蒡子辛、苦、性寒, 归肺、 胃经, 疏散风热、 清热解毒透疹、 宣肺利咽散肿。 上九药合用, 有清有解, 火邪得除, 甘草和中缓急, 调和诸药, 为方中使药。 邪去正安, 内外通和, 人体气机升降得益, 阴 平阳秘, 五脏元真通畅, 人即安和, 恢复健康。
本方最大特点为在大部清热泻火药中重用一味微温的荆芥穗, 且作为方中主药, 这 是因为: 1、 荆芥穗性微温, 但温而不燥, 方中用之即可防止大部清热泻火药配伍过于 寒凉, 避免寒凉遏邪之弊, 又不影响方剂清热泻火的主要功效; 2、 荆芥穗具有解表散 风功效, 协同北柴胡组成方剂解表的主要力量, 引导邪从表解; 3、 体内外试验证实荆 芥穗具有抗病毒和止咳作用, 目前未发现其他性温而有抗病毒作用的中药; 4、 试验证 实荆芥穗在合理范围内较大剂量比小剂量抗病毒作用明显, 且方剂协同功效发挥更佳; 其重要性及巧妙处不言而喻。传统医家多专注清热泻火, 药物皆为寒凉之品, 如多用白 僵蚕清热利咽, 然临床发现, 服药期间易腹泻、 热退后多遗留咳嗽难愈等问题, 究其根 源即为方药过于寒凉所致, 临床亦发现存在服用动物药白僵蚕过敏现象。本方另一重要 特点为重用酒黄连,酒黄连苦寒,功可清热燥湿,泻火解毒,为方中清解主要组成力量, 同时酒黄连入胃经, 可泻胃火, 运用恰当可防止和治疗邪传阳明经。
为达到更好的临床疗效, 本发明中药组合物还可与酒黄芩、板蓝根结合; 这是因为 酒黄芩是有名的清热泻火中药, 酒黄芩苦、 寒, 清热燥湿、 泻火解毒, 善清肺火及上焦 之实热; 板蓝根味苦性寒, 归心、 胃经, 功能清热解毒、凉血、利咽,用于温热病发热、 头痛、 喉痛等多种热毒炽盛之证。
为达到更好的临床疗效, 本发明中药组合物还可与升麻、 薄荷结合; 这是因为升麻 有清热解毒、 辛凉解表之功, 用治风热上攻、 阳明头痛, 也可主治外感风热夹湿之证, 切实提高临床疗效; 薄荷辛, 凉, 气香, 入肺、 肝经, 有疏散风热、 清热解表、 祛风消 肿、 利咽止痛之功效, 常用于风热感冒、 风热头痛、 目赤疼痛、 咽喉肿痛等。
为达到最佳临床疗效, 本发明中药组合物还可与败酱草、鱼腥草结合; 这是因为败 酱草辛、苦,微寒,有清热解毒、消痈排脓之功效,运用于热毒痈肿; 鱼腥草辛,微寒, 归肺经, 有清热解毒、 排脓功效, 用于肺热咳嗽等证。
本发明中药组合物是在多年中医疫病临床实践中总结运用出的经验方,加之科学的 实验依据, 各组份既能发挥各自的药理作用, 又能起到相互的协同作用, 使药理作用增 强,配方合理,药味精炼,该方用于治疗或预防甲型流感病毒的感染,只要见症有发热、 咳嗽、咯黄痰、咽痛、头痛身痛等, 即可应用,疗效确切, 且无毒副作用,在流行期间, 作为通用方用于治疗与预防皆有效, 剂型和制备工艺适合工业化大批量生产。
具体实施方式
本发明抗甲型流感病毒感染并止咳的中药组合物,包括下列重量份数的原料药: 荆 芥穗 5-25克、酒黄连 1-10克、玄参 1-10克、橘红 1-10克、桔梗 1_10克、北柴胡 1_10 克、 马勃 1-10克、 连翘 1-10克、 牛蒡子 1-15克、 甘草 1-10克。
实施方式 1 :
称取原料药荆芥穗 12克、 酒黄连 10克、 玄参 5克、 橘红 5克、 桔梗 5克、 北柴胡 5克、 马勃 5克、 连翘 5克、 牛蒡子 5克、 甘草 5克, 以上十味药物共 62克, 加水煎 煮合并滤液、浓縮、冷却,加乙醇使含醇量为 20-80%,回收乙醇,使上清液浓縮成稠膏, 备用。 加入 β _环糊精, 加热溶解、 搅拌、 滤过、 喷雾干燥热空气进风温度 180°C, 出 风温度 80°C, 喷干粉加入调味剂, 混匀, 物料在 40°C温度下干式制粒、 整粒、 分装成 袋, 即得本发明抗甲型流感病毒感染并止咳的颗粒剂。
实施方式 2: 称取原料药荆芥穗 20克、 酒黄连 10克、 玄参 5克、 橘红 5克、 桔梗 5克、 北柴胡 5克、 马勃 5克、 连翘 5克、 牛蒡子 5克、 甘草 5克, 以上十味药物共 70克, 然后按实施方式 1所 述的方法制成颗粒剂。
实施方式 3:
称取原料药荆芥穗 12克、 酒黄连 10克、 玄参 5克、 橘红 5克、 桔梗 5克、 北柴胡 5克、 马勃 5克、 连翘 5克、 牛蒡子 5克、 甘草 5克、 酒黄芩 5克 (后下药)、 板蓝根 5克, 以上十 二味药物共 72克, 然后按实施方式 1所述的方法制成颗粒剂。
实施方式 4:
称取原料药荆芥穗 20克、 酒黄连 10克、 玄参 5克、 橘红 5克、 桔梗 5克、 北柴胡 5克、 马勃 5克、 连翘 5克、 牛蒡子 5克、 甘草 5克、 酒黄芩 5克 (后下药)、 板蓝根 5克, 以上十 二味药物共 80克, 然后按实施方式 1所述的方法制成颗粒剂。
实施方式 5:
称取原料药荆芥穗 12克、 酒黄连 10克、 玄参 5克、 橘红 5克、 桔梗 5克、 北柴胡 5克、 马勃 5克、连翘 5克、牛蒡子 5克、甘草 5克、酒黄芩 5克(后下药)、板蓝根 5克、升麻 5克、 薄荷 5克(后下药), 以上十四味药物共 82克,然后按实施方式 1所述的方法制成颗粒剂。
实施方式 6:
称取原料药荆芥穗 20克、 酒黄连 10克、 玄参 5克、 橘红 5克、 桔梗 5克、 北柴胡 5克、 马勃 5克、连翘 5克、牛蒡子 5克、甘草 5克、酒黄芩 5克(后下药)、板蓝根 5克、升麻 5克、 薄荷 5克(后下药), 以上十四味药物共 90克,然后按实施方式 1所述的方法制成颗粒剂。
实施方式 7:
称取原料药荆芥穗 12克、 酒黄连 10克、 玄参 5克、 橘红 5克、 桔梗 5克、 北柴胡 5克、 马勃 5克、连翘 5克、牛蒡子 5克、甘草 5克、酒黄芩 5克(后下药)、板蓝根 5克、升麻 5克、 薄荷 5克 (后下药)、 败酱草 5克、 鱼腥草 5克, 以上十六味药物共 92克, 然后按实施方式 1所述的方法制成颗粒剂。
实施方式 8:
称取原料药荆芥穗 20克、 酒黄连 10克、 玄参 5克、 橘红 5克、 桔梗 5克、 北柴胡 5克、 马勃 5克、连翘 5克、牛蒡子 5克、甘草 5克、酒黄芩 5克(后下药)、板蓝根 5克、升麻 5克、 薄荷 5克 (后下药)、 败酱草 5克、 鱼腥草 5克, 以上十六味药物共 100克, 然后按实施方 式 1所述的方法制成颗粒剂。
实施方式 9:
称取原料药酒黄连 10克、 玄参 5克、 橘红 5克、 桔梗 5克、 北柴胡 5克、 马勃 5克、 连 翘 5克、牛蒡子 5克、甘草 5克、酒黄芩 5克(后下药)、板蓝根 5克、升麻 5克、薄荷 5克(后 下药), 以上十三味药物共 70克, 然后按实施方式 1所述的方法制成颗粒剂。 试验例 1: 中药组合物体外抗甲型流感病毒亚型的实验
测试原理: 以 MDCK (狗肾细胞)为病毒宿主, 测定样品抑制流感病毒甲型引起 MDCK 细胞病变程度。
测试材料和方法:
1.病毒株: 流感病毒甲型 A/粤防 /243/72 (H3N2)。
2. 样品处理:取实施例 1、 2、 3、 4、 5、 6、 7、 8、 9制得的稠膏加水溶解并分别制 成 lOOOmg/ml的溶液装瓶备用; 3000rpm离心 20分钟后取上清液, 用 50%的枸橼酸 钠调 pH7. 2〜7. 6, 倾入无菌试管中, 121 °C、 15— 20分钟高压灭菌, 取出后置 4°C 冰箱中保存备用; 实验时溶液样品用培养液 1 : 10稀释开始, 作 2倍稀释, 共 8个 稀释度。
3.阳性对照药: 达菲。
4.测试方法: MDCK细胞种 96孔培养板, 24小时后分别感染流感病毒甲型 A/粤防 /243/72 (H3N2) (感染量为 100个 TCID50), 吸附 2小时, 弃病毒液, 按以上稀释度 加入样品, 同时设细胞对照孔和病毒对照孔, 24小时观察细胞病变程度(CPE), 用 Reed-Muench法分别计算样品的半数有效浓度(IC5。), 并计算药物选择指数 (SI)。
测试结果
编号 IC50 SI
实施方式例 1组 1. 42mg/mL 1. 61
达菲组 0. 000022mg/mL ) 909. 1
实施方式例 2组 1. 23 mg/mL 2. 31
达菲组 0. 000156mg/mL
实施方式例 3组 1. 16mg/mL 2. 88
达菲组 0. 000036mg/mL
实施方式例 4组 0. 43mg/mL 5. 09
达菲组 0. 000093mg/mL
实施方式例 5组 0. 58mg/mL 4. 21
达菲组 0. 000012mg/mL
实施方式例 6组 0. 03mg/ml 6. 02
达菲组 0. 00027 lmg/ml
实施方式例 7组 0. 89mg/mL 3. 60
达菲组 0. 000113mg/mL 实施方式例 8组 0. 45mg/mL 5. 12
达菲组 0. 000033mg/mL
实施方式例 9组 1. 66mg/mL 1. 32
达菲组 0. 000096mg/mL
试验例 2: 中药荆芥穗、 防风体外抗甲型流感病毒亚型的实验
1、 实验原理、 测试方法、 实验设计同试验例 1.
2、 测试材料: 荆芥穗 1组为称取原料药荆芥穗 12g按照实施方式 1方法制得的稠膏, 荆芥穗 2组为称取原料药荆芥穗 20g按照实施方式 1方法制得的稠膏, 荆芥穗 3组 为称取原料药荆芥穗 30g按照实施方式 1方法制得的稠膏; 防风组为称取原料药防 风 20g按照实施方式 1方法制得的稠膏。 对照组为达菲。
3、 实验结果: 表 2
测试结果
编号 IC50 SI
荆芥穗 1组 1. 51mg/mL 1. 5
荆芥穗 2组 0. 43mg/mL 3. 1
荆芥穗 3组 0. 19mg/mL 5. 9
防风组 无效 无效
达菲组 0. 000063mg/mL 试验例 3: 中药荆芥穗对小鼠咳嗽影响的对比研究
1、 试验原理
小鼠吸入刺激性化学药物的气雾后, 刺激呼吸道感受器, 反射地引起咳嗽。
2、 材料与方法
2. 1 试剂及仪器 氨水、 蒸馏水, 生化仪等。
2. 2 动物 昆明小鼠 50只, 体质量 (25 ± 2) g, 雌雄各半, 由广州中医药大学附属深圳 医院动物实验中心提供, 实验前各组小鼠状态正常, 无咳嗽或其他不正常的现象。
2. 3 药物 抗感止咳颗粒, 由荆芥穗、牛蒡子、酒黄芩、酒黄连、板蓝根、橘红、桔梗、 马勃、连翘、玄参、升麻、北柴胡、薄荷、甘草组成; 荆芥穗组, 由原料药荆芥穗组成, 按照本发明实施方式 1所述方法制成颗粒剂; 抗感止咳颗粒去荆芥穗组, 由牛蒡子、 酒 黄芩、 酒黄连、 板蓝根、 橘红、 桔梗、 马勃、 连翘、 玄参、 升麻、 北柴胡、 薄荷、 甘草 组成, 按照本发明实施方式 1所述方法制成颗粒剂; 生药质量浓度为 100g / lOOmL, 生 药由广州中医药大学附属深圳医院中药房提供,经鉴定全部符合《中华人民共和国药典》 相关规定。氯雷他定分散片(商品名:雷宁,批准文号:国药准字 H20030208, 2010-12-08, 生产单位: 北京双鹭药业股份有限公司)。
2. 4 分组 将小鼠随机分为抗感止咳颗粒组、 荆芥穗组、 抗感止咳颗粒去荆芥穗组、 空 白对照组, 西药对照组, 每组 10只。 常规伺养 1周后, 按照 《药理实验方法学》 相关 内容, 按 60kg体质量成人换算小鼠给药剂量。 抗感止咳颗粒组、 荆芥穗组、 抗感止咳 颗粒去荆芥穗组分别灌胃抗感止咳颗粒 2mL / 20g、荆芥穗颗粒剂 2ml/20g、抗感止咳颗 粒去荆芥穗颗粒剂 2ml/20g ; 西药对照组灌胃氯雷他定分散片 2mL / 20g : 空白组灌胃等 剂量蒸馏水。 每日 1次, 时间为 4d。
2. 5 引咳实验 实验前小鼠禁食不禁水 12h, 给药 lh后, 分别置于 20cmX 20cmX 15cm 密闭有机玻璃试验箱内, 将浓氨水 50mL置于雾化器内, 向实验箱内通雾化氨水 30s。 结束后, 立即取出小鼠, 观察。
2. 6 观察方法: 以小鼠腹肌收縮或胸部收縮, 同时张嘴记为一次咳嗽, 有时可有咳嗽 声者, 算作 "有咳嗽", 否则算作 "无咳嗽", 记录 3分钟内小鼠咳嗽次数。
2. 7 统计学方法 采用 SPSS16. 0统计软件, 采用独立样本检验和单因素方差分析, 计 量资料以 ( ±S) 表示, P〈0. 05为差异有统计学意义。
3、 结果
中药对小鼠咳嗽次数的影响 (见下表)
抗感止咳颗粒组、荆芥穗组、 西药对照组的咳嗽次数明显比空白对照组、抗感止咳颗粒 去荆芥穗组低. 对小鼠的咳嗽有效。 而抗感止咳颗粒组效果尤为明显, 荆芥穗组次之, 抗感止咳颗粒去荆芥穗组基本无效。 试验说明荆芥穗有非常好的止咳作用。
表 3 各组小鼠咳嗽次数比较( 士 S)
组别 N 剂量 (ml/20g) 咳嗽次数
抗感止咳颗粒组 10 2 24. 3 ± 7· 8** 荆芥穗组 10 2 33. 4 ±8. 2* 抗感止咳颗粒去荆芥穗组 10 2 45. 9± 12. 7 氯雷他定分散片组 10 2 32. 2 ± 10· 5* 对照组 10 2ml蒸馏水 46. 7 ±8. 9 注: 与对照组比较: *P<0.05, ** P<0.05.
试验例 4: 中药组合物抗甲型流感病毒感染并止咳的临床疗效试验
1.1 资料和方法
1.1.1 临床资料
本组病例均为 2009年确诊的新型甲型 H1N1流感的患者, 年龄 11~69岁, 90例符 合下列诊断标准的患者, 随机分为治疗一组 (实施方式例 9组) 30例, 治疗二组 (实 施方式例 6组) 30例, 对照组 (达菲) 30例。 各组在性别、 年龄、 病程和病情分布上 无统计学意义 (P>0.05)。
1.1.2 诊断标准
(1) 与新型 H1N1患者有密切接触史;
(2) 两天内出现以发热、 咳嗽、 咽痛为主的流感临床表现及相应体征者;
(3) 鼻咽拭子 RT-PCR检测, 新型 H1N1病毒为阳性者。
1.1.3 排除标准
(1) 伴发肺炎、 急慢性鼻窦炎、 肺结核等疾病患者;
(2) 血 WBC〉1L 0X107L或中性粒细胞〉75%;
(3) 合并严重的心、 脑、 肺、 肝、 肾和血液系统等严重原发性疾病, 如病毒性肝炎、 血友病、 糖尿病、 精神病患者等;
(4) 就诊前已接受其它针对本病的内服药物如抗病毒药、 抗生素、 中药等药物治疗; 或正在参加其它临床试验的患者;
(5) 妊娠期、 哺乳期妇女;
(6) 过敏体质, 如对两种以上药物或食物过敏史者, 已知对本药物成份过敏者。 1.2 治疗方法
治疗一组给予 (实施方式例 9组) 的中药组合物颗粒剂, 口服, 每日两次, 每次用 量相当于各生药材量见实施方式例 9组; 治疗二组给予 (实施方式例 6组) 的中药组合物 颗粒剂, 口服, 每日两次, 每次用量相当于各生药材量见实施方式例 6组; 对照组用达 菲 (磷酸奥司他韦胶囊) 75mg/次, 每日 2次, 口服。 儿童酌减。 疗程为 5天。
1.3 疗效标准
显效: 24h内体温正常, 咳嗽、 咽痛等临床症状明显缓解, 从鼻咽拭子中分离的病 毒经 RT-PCR检测, 新型 H1N1病毒 RNA在 72小时内转阴。
有效: 72h内体温正常, 咳嗽、 咽痛等临床症状有所缓解, 从鼻咽拭子中分离的病 毒经 RT-PCR检测, 新型 H1N1病毒 RNA在 72小时内转阴。
无效: 治疗 5天仍发热, 咳嗽、 咽痛等临床症状未缓解, 从鼻咽拭子中分离的病毒 经 RT-PCR检测, 新型 H1N1病毒 RNA结果仍为阳性。
1. 4 结果
运用本发明(实施方式例 9组)、 (实施方式例 6组)中药组合物和对照达菲组进行 抗甲型流感病毒感染临床实验, 结果表明: 比较三组患者发热、 咳嗽、 咯痰等临床改善 情况、 72小时病毒核酸转阴率、 平均退热时间等治疗。 治疗一组临床改善总有效率 59. 33%, 72小时病毒核酸转阴率 11.13%, 平均退热时间 41.23小时; 治疗二组临床改 善总有效率 71 · 58%, 72小时病毒核酸转阴率 33.55%, 平均退热时间 23.38小时; 对照 组临床改善总有效率 73. 11%, 72小时病毒核酸转阴率 36.12%, 平均退热时间 27.06小 时。
以上内容是结合具体的实施方式对本发明所作的进一步详细说明,不能认定本发明 的具体实施只局限于这些说明。对于本发明所属技术领域的普通技术人员来说, 在不脱 离本发明构思的前提下,还可以做出若干简单推演或替换, 都应当视为属于本发明的保 护范围。

Claims

权利要求书
1. 一种抗甲型流感病毒感染并止咳的中药组合物, 其特征在于: 包括下列重量份 数的原料药: 荆芥穗 1-30、 酒黄连 1-30、 玄参 1-30、 橘红 1-30、 桔梗 1_30、 北柴胡 1-30、 马勃 1-30、 连翘 1-30、 牛蒡子 1-30、 甘草 1-15。
2. 根据权利要求 1所述的抗甲型流感病毒感染并止咳的中药组合物, 其特征是: 所述原料药为: 荆芥穗 5-25克、 酒黄连 1-10克、 玄参 1-10克、 橘红 1-10克、 桔梗 1-10克、北柴胡 1-10克、马勃 1-10克、连翘 1-10克、牛蒡子 1-15克、甘草 1-10克。
3. 根据权利要求 2所述的抗甲型流感病毒感染并止咳的中药组合物, 其特征是: 其中原料药还包括: 酒黄芩 1-20克、 板蓝根 1-20克。
4. 根据权利要求 3所述的抗甲型流感病毒感染并止咳的中药组合物, 其特征是: 其中原料药还包括: 升麻 1-20克、 薄荷 1-20克。
5. 根据权利要求 4所述的抗甲型流感病毒感染并止咳的中药组合物, 其特征是: 其中原料药还包括: 败酱草 1-20克、 鱼腥草 1-20克。
6. 权利要求 1或者 2所述中药组合物的制备方法, 它包括下列步骤:
Φ取荆芥穗、 酒黄连、 玄参、 橘红、 桔梗、 北柴胡、 马勃、 连翘、 牛蒡子、 甘草加 水煎煮合并滤液、 浓縮、 冷却, 加乙醇使含醇量 20-80% (V/V) ,回收乙醇, 使上清液 浓縮成稠膏, 备用:
②将制备的稠膏与颗粒剂常用辅料混合, 制粒, 干燥和分装成袋, 即可制备成抗甲 型流感病毒感染并止咳的颗粒剂; 或将稠膏与口服液常用辅料混合, 煮沸, 加水稀释, 静置, 过滤, 混匀分装成瓶, 即可制备成抗甲型流感病毒感染并止咳的口服液; 或将稠 膏加入蔗糖、 矫味剂、 防腐剂, 煮沸, 加水稀释至 1000ml , 静置, 滤过, 混匀, 分装, 即得抗甲型流感病毒感染并止咳的糖浆,其中所述蔗糖重量〉 450g, 所述矫味剂为甜菊 苷、 糖精钠、 安塞蜜、 甘草甜素、 环已烷氨基磺酸、 天冬酰胺、 醇糖、 天冬甜精、 薄荷 脑、 各种香精及各种果味料, 用量为 0.广 10%, 所述防腐剂为山梨酸及其钾钠盐用量为 <0. 3%、 羟苯甲酯类用量为 <0. 05 %, 所述分装使用的包材为玻璃瓶、 塑料瓶; 或将制 备的稠膏与片剂常用辅料混合、 压片, 即可制备成抗甲型流感病毒感染并止咳的片剂; 或将稠膏加入胶囊剂常用辅料, 干燥、粉碎装入胶囊, 即可制备成抗甲型流感病毒感染 并止咳的胶囊。
7. 根据权利要求 3所述中药组合物的制备方法, 它包括下列步骤:
Φ取荆芥穗、 酒黄连、 玄参、 橘红、 桔梗、 北柴胡、 马勃、 连翘、 牛蒡子、 甘草、 酒黄芩、 板蓝根加水煎煮合并滤液、 浓縮、 冷却, 加乙醇使含醇量 20-80% ( V/V) ,回 收乙醇, 使上清液浓縮成稠膏, 备用: ②将制备的稠膏与颗粒剂常用辅料混合, 制粒, 干燥和分装成袋, 即可制备成抗甲 型流感病毒感染并止咳的颗粒剂; 或将稠膏与口服液常用辅料混合, 煮沸, 加水稀释, 静置, 过滤, 混匀分装成瓶, 即可制备成抗甲型流感病毒感染并止咳的口服液; 或将稠 膏加入蔗糖、 矫味剂、 防腐剂, 煮沸, 加水稀释至 1000ml , 静置, 滤过, 混匀, 分装, 即得抗甲型流感病毒感染并止咳的糖浆,其中所述蔗糖重量〉 450g, 所述矫味剂为甜菊 苷、 糖精钠、 安塞蜜、 甘草甜素、 环已烷氨基磺酸、 天冬酰胺、 醇糖、 天冬甜精、 薄荷 脑、 各种香精及各种果味料, 用量为 0.广 10%, 所述防腐剂为山梨酸及其钾钠盐用量为 <0. 3%、 羟苯甲酯类用量为 <0. 05 %, 所述分装使用的包材为玻璃瓶、 塑料瓶; 或将制 备的稠膏与片剂常用辅料混合、 压片, 即可制备成抗甲型流感病毒感染并止咳的片剂; 或将稠膏加入胶囊剂常用辅料, 干燥、粉碎装入胶囊, 即可制备成抗甲型流感病毒感染 并止咳的胶囊。
8. 权利要求 4所述中药组合物的制备方法, 它包括下列步骤:
Φ取荆芥穗、 酒黄连、 玄参、 橘红、 桔梗、 北柴胡、 马勃、 连翘、 牛蒡子、 甘草、 酒黄芩、板蓝根、 升麻、 薄荷加水煎煮合并滤液、 浓縮、 冷却, 加乙醇使含醇量 20-80% (V/V) ,回收乙醇, 使上清液浓縮成稠膏, 备用:
②将制备的稠膏与颗粒剂常用辅料混合, 制粒, 干燥和分装成袋, 即可制备成抗甲 型流感病毒感染并止咳的颗粒剂; 或将稠膏与口服液常用辅料混合, 煮沸, 加水稀释, 静置, 过滤, 混匀分装成瓶, 即可制备成抗甲型流感病毒感染并止咳的口服液; 或将稠 膏加入蔗糖、 矫味剂、 防腐剂, 煮沸, 加水稀释至 1000ml , 静置, 滤过, 混匀, 分装, 即得抗甲型流感病毒并止咳感染的糖浆,其中所述蔗糖重量〉 450g, 所述矫味剂为甜菊 苷、 糖精钠、 安塞蜜、 甘草甜素、 环已烷氨基磺酸、 天冬酰胺、 醇糖、 天冬甜精、 薄荷 脑、 各种香精及各种果味料, 用量为 0.广 10%, 所述防腐剂为山梨酸及其钾钠盐用量为 <0. 3%、 羟苯甲酯类用量为 <0. 05 %, 所述分装使用的包材为玻璃瓶、 塑料瓶; 或将制 备的稠膏与片剂常用辅料混合、 压片, 即可制备成抗甲型流感病毒感染并止咳的片剂; 或将稠膏加入胶囊剂常用辅料, 干燥、粉碎装入胶囊, 即可制备成抗甲型流感病毒感染 并止咳的胶囊。
9. 权利要求 5所述中药组合物的制备方法, 它包括下列步骤:
Φ取荆芥穗、 酒黄连、 玄参、 橘红、 桔梗、 北柴胡、 马勃、 连翘、 牛蒡子、 甘草、 酒黄芩、 板蓝根、 升麻、 薄荷、 败酱草、 鱼腥草加水煎煮合并滤液、 浓縮、 冷却, 加乙 醇使含醇量 20-80% (V/V) ,回收乙醇, 使上清液浓縮成稠膏, 备用:
②将制备的稠膏与颗粒剂常用辅料混合, 制粒, 干燥和分装成袋, 即可制备成抗甲 型流感病毒感染并止咳的颗粒剂; 或将稠膏与口服液常用辅料混合, 煮沸, 加水稀释, 静置, 过滤, 混匀分装成瓶, 即可制备成抗甲型流感病毒感染并止咳的口服液; 或将稠 膏加入蔗糖、 矫味剂、 防腐剂, 煮沸, 加水稀释至 1000ml , 静置, 滤过, 混匀, 分装, 即得抗甲型流感病毒感染并止咳的糖浆,其中所述蔗糖重量〉 450g, 所述矫味剂为甜菊 苷、 糖精钠、 安塞蜜、 甘草甜素、 环已烷氨基磺酸、 天冬酰胺、 醇糖、 天冬甜精、 薄荷 脑、 各种香精及各种果味料, 用量为 0.广 10%, 所述防腐剂为山梨酸及其钾钠盐用量为 <0. 3%、 羟苯甲酯类用量为 <0. 05 %, 所述分装使用的包材为玻璃瓶、 塑料瓶; 或将制 备的稠膏与片剂常用辅料混合、 压片, 即可制备成抗甲型流感病毒感染并止咳的片剂; 或将稠膏加入胶囊剂常用辅料, 干燥、粉碎装入胶囊, 即可制备成抗甲型流感病毒感染 并止咳的胶囊。
10. 根据权利要求 1〜5所述的抗甲型流感病毒感染并止咳的中药组合物, 其特征 在于: 所述的组合物的剂型为: 颗粒剂、 口服液、糖浆、片剂、胶囊、 口崩片、泡腾片、 滴丸、 含嗽液、 漱口水。
11. 根据权利要求 1〜5所述的抗甲型流感病毒感染并止咳的中药组合物,其特征在于: 临床上可用于治疗或预甲型新型 H1N1和 /或甲型 H3N2流感病毒的感染及其产生的咳嗽。
PCT/CN2013/076598 2013-05-31 2013-05-31 一种抗甲型流感病毒感染并止咳的中药组合物及其制备方法 WO2014190555A1 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2013/076598 WO2014190555A1 (zh) 2013-05-31 2013-05-31 一种抗甲型流感病毒感染并止咳的中药组合物及其制备方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2013/076598 WO2014190555A1 (zh) 2013-05-31 2013-05-31 一种抗甲型流感病毒感染并止咳的中药组合物及其制备方法

Publications (1)

Publication Number Publication Date
WO2014190555A1 true WO2014190555A1 (zh) 2014-12-04

Family

ID=51987910

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2013/076598 WO2014190555A1 (zh) 2013-05-31 2013-05-31 一种抗甲型流感病毒感染并止咳的中药组合物及其制备方法

Country Status (1)

Country Link
WO (1) WO2014190555A1 (zh)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106236807A (zh) * 2016-07-20 2016-12-21 深圳神农春天植物活性物质开发有限公司 防治流感病毒组合物和中药复方口腔速溶膜制剂
CN106266707A (zh) * 2016-09-14 2017-01-04 四川聚豪生物科技有限公司 一种治疗外感风热病的汤剂药物及制备方法
CN107334923A (zh) * 2017-01-03 2017-11-10 徐延玲 一种治疗小儿咳嗽的中药组合物及其制备方法和用途
CN108498655A (zh) * 2018-06-04 2018-09-07 湖南中嘉药物开发有限公司 一种用于清热解毒的蓝金口服液及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1682842A (zh) * 2005-03-01 2005-10-19 广州白云山制药股份有限公司 一种消炎解毒的中药组合物及其制备方法和用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1682842A (zh) * 2005-03-01 2005-10-19 广州白云山制药股份有限公司 一种消炎解毒的中药组合物及其制备方法和用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GUO CHUNXIA: "Bàijiàngc?o de línchuáng x?nyòng", SHAANXI JOURNAL OF CHINESE MEDICINE, vol. 31, no. 5, 31 December 2010 (2010-12-31), pages 600 AND 601 *
HANG HAIYING ET AL.: "Kàng líug?n bìngdú zh?ngyào yánj?u jìnzh?n", JOURNAL OF PRACTICAL TRADITIONAL CHINESE MEDICINE, vol. 28, no. 5, 31 May 2012 (2012-05-31), pages PAGES 439 AND 440 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106236807A (zh) * 2016-07-20 2016-12-21 深圳神农春天植物活性物质开发有限公司 防治流感病毒组合物和中药复方口腔速溶膜制剂
CN106236807B (zh) * 2016-07-20 2020-08-14 深圳神农特医食品有限公司 防治流感病毒组合物和中药复方口腔速溶膜制剂
CN106266707A (zh) * 2016-09-14 2017-01-04 四川聚豪生物科技有限公司 一种治疗外感风热病的汤剂药物及制备方法
CN107334923A (zh) * 2017-01-03 2017-11-10 徐延玲 一种治疗小儿咳嗽的中药组合物及其制备方法和用途
CN108498655A (zh) * 2018-06-04 2018-09-07 湖南中嘉药物开发有限公司 一种用于清热解毒的蓝金口服液及其制备方法
CN108498655B (zh) * 2018-06-04 2021-02-02 湖南中嘉药物开发有限公司 一种用于清热解毒的蓝金口服液及其制备方法

Similar Documents

Publication Publication Date Title
Gajewski et al. Potential of herbal products in prevention and treatment of COVID-19. Literature review
CN102085311B (zh) 预防或治疗感冒和/或流行性感冒的中药组合物及其制备方法和用途
WO2011063553A1 (zh) 一种治疗由甲型h1n1等流感病毒引起的流感的中药
CN1724040A (zh) 治疗小儿感冒及反复感冒的中成药及其制备方法
CN102319294B (zh) 双香草制剂及其制备方法
CN102641356B (zh) 一种治疗呼吸道病毒感染性疾病的中药组合物及其制备方法
KR20220098360A (ko) 개나리-황기 복방제제 및 그 제조방법과 용도
WO2014190555A1 (zh) 一种抗甲型流感病毒感染并止咳的中药组合物及其制备方法
CN105998599A (zh) 一种治疗病毒性呼吸道感染的中药组合物及其制备方法
CN102657804B (zh) 一种治疗病毒性感冒的中药组合物及其制备方法
CN1437963A (zh) 治疗感冒的药物及其制备方法
WO2011143844A1 (zh) 一种治疗甲型流感病毒亚型感染的中药组合物及其制备方法
CN102641335A (zh) 一种治疗上呼吸道病毒感染的中药组合物及其制备方法
CN116139237B (zh) 一种防治新型冠状病毒等所致呼吸道感染的中药组合物及其应用
CN1150927C (zh) 一种治疗急慢性咽喉炎,扁桃体炎的药物及其生产方法
CN110193061A (zh) 一种治疗或预防儿童流感病毒感染的中药颗粒剂的制备及应用
CN113577187B (zh) 一种治疗流行性感冒的中药组合物、中药提取物及其制备方法和应用
CN102210773A (zh) 一种治疗小儿肺炎的中药巴布膏剂和制备方法及其应用
CN102188574B (zh) 一种治疗甲型流感病毒性支气管炎的中药组合物及其制备方法
CN102451401A (zh) 一种维c银翘的处方
CN107773695A (zh) 一种用于治疗扁平疣的中药
CN105816583B (zh) 一种治疗感冒的复方药物及其制备方法
CN105267395A (zh) 复方鱼腥草糖浆提取液、复方鱼腥草糖浆及其制备方法
WO2012075646A1 (zh) 治疗甲型流感病毒亚型感染的中药组合物及其制备方法
WO2022253267A1 (zh) 一种治疗儿童感冒的中药组合物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13885813

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13885813

Country of ref document: EP

Kind code of ref document: A1